Skip to main content

Table 1 Radiological stages, lung function tests parameters, frequency of patients with Löfgren syndrome, abnormal laboratory results, % of patients on treatment and disease duration in patients at initial evaluation (V1) and follow-up (V2) visits.

From: Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up

Feature Visit 1 Visit 2
Stage I 23 (57.5%) 13 (-10 with CR)
Stage II 9 (22.5%) 8 (-1 with CR)
Stage III 8 (20%) 8 (no CR)
FEV1 (% predicted) 92.6 ± 3.2 93.8 ± 3.1
FVC (% predicted) 97.9 ± 3.0 99.7 ± 2.9
FEV1/FVC (%) 0.81 ± 0.02 0.80 ± 0.02
DLCOc (% predicted) 87.3 ± 3.4 87.7 ± 3.7
LS present and past 20 (50%) -
LS present 15 (37.5%) 0
SACE > 68 IU/L 11 (27.5%) 5 (12.5%)
S-Ca2+ > 2.62 mmol/L 1 (2.5%) 2 (5%)
U-Ca2+ > 7.5 mmol/24 h 3 (7.5%) 5 (12.5%)
CRP > 5 mg/L 15 (37.5%) 5 (12.5%)
On treatment 0 8 (20%)
T from first symptoms to V1
(weeks, median: 25-75 percentile)
10 [4-60] -
  1. CR – complete remission, DLCOc – diffusion capacity for CO corrected for hemoglobin, FEV1 #8211; forced expiratory volume in 1st second of expiration, FVC – forced vital capacity, LS – Löfgren syndrome, S – serum, SACE – serum angiotensin converting enzyme, T – time, U – urine.